Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD‐L1)‐mediated immunosuppression
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Aging is characterized by a progressive loss of physiological integrity, while cancer represents one of the primary pathological factors that severely threaten human lifespan and healthspan. In clinical oncology, drug resistance limits the efficacy of most anticancer treatments, and identification of major mechanisms remains a key to solve this challenging issue. Here, we highlight the multifaceted senescence‐associated secretory phenotype (SASP), which comprises numerous soluble factors including amphiregulin (AREG). Production of AREG is triggered by DNA damage to stromal cells, which passively enter senescence in the tumor microenvironment (TME), a process that remarkably enhances cancer malignancy including acquired resistance mediated by EGFR. Furthermore, paracrine AREG induces programmed cell death 1 ligand (PD‐L1) expression in recipient cancer cells and creates an immunosuppressive TME via immune checkpoint activation against cytotoxic lymphocytes. Targeting AREG not only minimized chemoresistance of cancer cells, but also restored immunocompetency when combined with classical chemotherapy in humanized animals. Our study underscores the potential of in vivo SASP in driving the TME‐mediated drug resistance and shaping an immunosuppressive niche, and provides the proof of principle of targeting major SASP factors to improve therapeutic outcome in cancer medicine, the success of which can substantially reduce aging‐related morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“…studies of patient populations have discovered that there are dif‐ ferent types of TME, whose classification can be improved by next‐ generation technologies to inform success or failure of current ICB agents and encourage development of advanced immunotherapeu‐ tics (Binnewies et al., 2018).”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 1×
“…cells, the SASP is now es‐ tablished as an important contributor in the development of multiple aging‐related complications, including atherosclerosis, osteoarthri‐ tis, physical frailty, and systemic inflammation (Childs et al., 2016; Demaria et al., 2017; Jeon et al., 2017; Zhu et al., 2015).”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Thus, in contrary to the well‐established concept of immunosurveillance enhanced by the SASP (Kang et al., 2011; Xue et al., 2007), our findings disclosed an immunosuppres‐ sive function of the SASP manifested by the treatment‐damaged TME.”
ResultOncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
Kuilman, T., Michaloglou, C., Vredeveld, L. C. W., Douma, S., van Doorn, R., Desmet, C. J., Aarden, L. A., Mooi, W. J., & Peeper, D. S. (2008) · Cell · doi:10.1016/j.cell.2008.03.039 · Cited by 2,086 · cited 1×
“…arable damage in benign stromal cells surrounding the tumor foci (Faget, Ren, & Stewart, 2019; Sun, Coppe, & Lam, 2018), and gener‐ ate a large number of senescent cells that display a senescence‐as‐ sociated secretory phenotype (SASP; Acosta et al., 2008; Coppe et al., 2008; Kuilman et al., 2008).”
BackgroundRevisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866 · cited 1×
“Although the development of advanced human malignancies sub‐ stantially restrains the spectrum of therapeutic options, numerous data suggested that clinical failure is indeed intertwined with drug resistance (Robey et al., 2018).”
BackgroundChemokine signaling via the CXCR2 receptor reinforces senescence
Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801 · cited 1×
“…arable damage in benign stromal cells surrounding the tumor foci (Faget, Ren, & Stewart, 2019; Sun, Coppe, & Lam, 2018), and gener‐ ate a large number of senescent cells that display a senescence‐as‐ sociated secretory phenotype (SASP; Acosta et al., 2008; Coppe et al., 2008; Kuilman et al., 2008).”
BackgroundSenescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621 · cited 1×
“Thus, in contrary to the well‐established concept of immunosurveillance enhanced by the SASP (Kang et al., 2011; Xue et al., 2007), our findings disclosed an immunosuppres‐ sive function of the SASP manifested by the treatment‐damaged TME.”
ResultImmunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Jeon, O. H., Kim, C., Laberge, R.-M., Demaria, M., Rathod, S., Vasserot, A. P., Chung, J. W., Kim, D. H., Poon, Y., David, N., et al. (2017) · Nature Medicine · doi:10.1038/nm.4324 · Cited by 1,515 · cited 2×
“…cells, the SASP is now es‐ tablished as an important contributor in the development of multiple aging‐related complications, including atherosclerosis, osteoarthri‐ tis, physical frailty, and systemic inflammation (Childs et al., 2016; Demaria et al., 2017; Jeon et al., 2017; Zhu et al., 2015).”
BackgroundSelf-citationCellular senescence promotes adverse effects of chemotherapy and cancer relapse
Demaria, M., O'Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0241 · Cited by 1,338 · cited 3×
“…cells, the SASP is now es‐ tablished as an important contributor in the development of multiple aging‐related complications, including atherosclerosis, osteoarthri‐ tis, physical frailty, and systemic inflammation (Childs et al., 2016; Demaria et al., 2017; Jeon et al., 2017; Zhu et al., 2015).”
BackgroundSelf-citationUnmasking senescence: context-dependent effects of SASP in cancer
Faget, D. V., Ren, Q., & Stewart, S. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0156-2 · Cited by 863
Cellular senescence and its effector programs
Salama, R., Sadaie, M., Hoare, M., & Narita, M. (2014) · Genes & Development · doi:10.1101/gad.235184.113 · Cited by 855
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793 · cited 10×
“…comprising mainly fibroblasts but with a minor per‐ centage of nonfibroblast cell lineages including endothelial cells and smooth muscle cells, produces a large number of SASP factors after exposure to cytotoxic insults, specifically genotoxic chemotherapy or ionizing radiation (Sun et al., 2012).”
BackgroundMethodInfluentialSelf-citationCD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462 · cited 1×
“…either intrinsic or acquired resistance of cancer cells, the mechanisms of which frequently im‐ plicate a preexisting tumor microenvironment (TME), a pathological entity that functionally supports the outgrowth of resistant clones even in clinical settings (Chen et al., 2018; Gandhi & Das, 2019).”
BackgroundDNA Damage-Mediated Induction of a Chemoresistant Niche
Gilbert, L. A., & Hemann, M. T. (2010) · Cell · doi:10.1016/j.cell.2010.09.043 · Cited by 428 · cited 1×
“…of soluble factors including cyto‐ kines, chemokines, growth factors, and proteases generated by the SASP promotes chemoresistance of surviving cancer cells after early waves of administration, specifically in genotoxic settings (Gilbert & Hemann, 2010; Obenauf et al., 2015; Sun et al., 2012).”
BackgroundCoppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · cited 2×
“…or chemok‐ ines per se, such as IL‐8 and CXCL3, diverse growth factors including amphiregulin (AREG) are produced by senescent human stromal cells (Coppe et al., 2008; Sun et al., 2012), suggesting that the impact of the SASP on tumor progression could be complicated and multidi‐ mensional.”
BackgroundSelf-citationCellular senescence: the sought or the unwanted?
Sun, Y., Coppé, J.-P., & Lam, E. W.-F. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.08.002 · Cited by 208
Self-citationZhang, B., Fu, D., Xu, Q., Cong, X., Wu, C., Zhong, X., Ma, Y., Lv, Z., Chen, F., Han, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04010-4 · Cited by 157
Self-citation
Cited by
Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice
Xu, Q., Fu, Q., Li, Z., Liu, H., Wang, Y., Lin, X., He, R., Zhang, X., Ju, Z., Campisi, J., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00491-8 · Cited by 341
Self-citationCellular senescence and SASP in tumor progression and therapeutic opportunities
Dong, Z., Luo, Y., Yuan, Z., Tian, Y., Jin, T., & Xu, F. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02096-7 · Cited by 259
Senescent Cells: Emerging Targets for Human Aging and Age-Related Diseases
Song, S., Lam, E. W.-F., Tchkonia, T., Kirkland, J. L., & Sun, Y. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.03.008 · Cited by 195
“In solid tumors, the SASP can simultaneously drive cancer resistance and establish an immunodeficient niche by upregulating PD-L1 expression in cancer cells, thereby activating the immune checkpoint and exacerbating pathologies even after therapeutic intervention [34].”
BackgroundSelf-citationTargeting Senescent Cells for a Healthier Aging: Challenges and Opportunities
Song, S., Tchkonia, T., Jiang, J., Kirkland, J. L., & Sun, Y. (2020) · Advanced Science · doi:10.1002/advs.202002611 · Cited by 129
Self-citation
Metadata
- Authors
- Xu, Q., Long, Q., Zhu, D., Fu, D., Zhang, B., Han, L., Qian, M., Guo, J., Xu, J., Cao, L., Chin, Y. E., Coppé, J., Lam, E. W. ‐., Campisi, J., & Sun, Y.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2019-09-07
- Volume
- 18
- Issue
- 6
- Pages
- e13027-e13027
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W2972176863
- Cited by
- 139
- References
- 19
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.